|
Index | - | P/E | - | EPS (ttm) | -0.79 | Insider Own | 0.80% | Shs Outstand | 12.07M | Perf Week | -6.27% |
Market Cap | 28.88M | Forward P/E | - | EPS next Y | -0.63 | Insider Trans | -22.79% | Shs Float | 11.78M | Perf Month | 56.79% |
Income | -5.80M | PEG | - | EPS next Q | -0.17 | Inst Own | 10.40% | Short Float | 3.89% | Perf Quarter | 59.75% |
Sales | 0.60M | P/S | 48.13 | EPS this Y | 63.60% | Inst Trans | - | Short Ratio | 0.23 | Perf Half Y | 21.53% |
Book/sh | 1.14 | P/B | 2.23 | EPS next Y | 21.80% | ROA | -49.70% | Target Price | - | Perf Year | 103.20% |
Cash/sh | 1.28 | P/C | 1.99 | EPS next 5Y | - | ROE | -54.60% | 52W Range | 1.18 - 4.34 | Perf YTD | 2.83% |
Dividend | - | P/FCF | - | EPS past 5Y | 36.60% | ROI | -67.80% | 52W High | -41.47% | Beta | 0.66 |
Dividend % | - | Quick Ratio | 9.90 | Sales past 5Y | -3.10% | Gross Margin | - | 52W Low | 115.25% | ATR | 0.23 |
Employees | 8 | Current Ratio | 9.90 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 58.48 | Volatility | 6.61% 11.05% |
Optionable | No | Debt/Eq | 0.00 | EPS Q/Q | 88.70% | Profit Margin | - | Rel Volume | 0.13 | Prev Close | 2.62 |
Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | Oct 28 AMC | Payout | - | Avg Volume | 1.98M | Price | 2.54 |
Recom | 2.00 | SMA20 | 6.39% | SMA50 | 32.66% | SMA200 | 52.09% | Volume | 257,072 | Change | -3.05% |
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh for studies related to head and neck cancer. The company is based in San Diego, California. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
open in yahoo | open in reuters | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite